| Symbol | TBPH |
|---|---|
| Name | THERAVANCE BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | Caribbean |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | UGLAND HOUSE, SOUTH CHURCH STREET,GEORGE TOWN, PO BOX 309, GRAND CAYMAN, KY1-1104, Cayman Islands |
| Telephone | +1 650 808-6000 |
| Fax | — |
| — | |
| Website | https://www.theravance.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001583107 |
| Description | Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Additional info from NASDAQ: |
2026-08-15 11:07
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Read more
2026-08-14 17:21
New Form SCHEDULE 13G/A - Theravance Biopharma, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001493152-26-038373 <b>Size:</b> 10 KB
Read more
2026-08-14 11:09
New Form SCHEDULE 13G/A - Theravance Biopharma, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001013594-26-000901 <b>Size:</b> 14 KB
Read more
2026-08-11 09:14
New Form PREM14A - Theravance Biopharma, Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001104659-26-093784 <b>Size:</b> 3 MB
Read more
2026-08-10 12:35
(19% Negative) THERAVANCE BIOPHARMA, INC. (TBPH) Reports Q3 2026 Financial Results
Read more
2026-08-10 12:30
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more
2026-06-29 17:36
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
Read more
2026-06-29 15:19
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Read more
2026-06-29 14:02
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
Read more
2026-06-29 10:30
(19% Negative) THERAVANCE BIOPHARMA, INC. (TBPH) Announces Business Combination
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07133880 | Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Lo… | Phase4 | COPD (Chronic Obstructive Pulmonary Disease) | Recruiting | 2023-12-05 | 2026-12-01 | ClinicalTrials.gov |
| NCT05696717 | Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomat… | Phase3 | Symptomatic Neurogenic Orthostatic Hypotension | Active_Not_Recruiting | 2023-06-27 | 2028-01-01 | ClinicalTrials.gov |
| NCT05091723 | TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygen… | Phase1 | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | Completed | 2021-10-13 | 2021-11-24 | ClinicalTrials.gov |
| NCT04681079 | Comparison of Viral Particle Dispersion Following Administration of an MDI or N… | — | COVID-19 | Completed | 2021-05-04 | 2022-01-18 | ClinicalTrials.gov |
| NCT04688632 | Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects | Phase1 | Symptomatic Neurogenic Orthostatic Hypertension | Completed | 2021-01-18 | 2021-03-26 | ClinicalTrials.gov |
| NCT04315558 | Revefenacin in Acute Respiratory Insufficiency in COPD | Phase2 | COPD | Completed | 2020-11-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT04587713 | Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects | Phase1 | Intestinal Disorder | Completed | 2020-10-16 | 2020-12-27 | ClinicalTrials.gov |
| NCT04589260 | TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic P… | Phase1 | Idiopathic Pulmonary Fibrosis (IPF) | Terminated | 2020-10-15 | 2021-10-04 | ClinicalTrials.gov |
| NCT03920254 | TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study | Phase2 | Ulcerative Colitis (UC) | Terminated | 2020-07-23 | 2021-10-27 | ClinicalTrials.gov |
| NCT04402866 | TD-0903 for ALI Associated With COVID-19 | Phase2 | Acute Lung Injury (ALI) Associated With COVID-19 | Completed | 2020-06-24 | 2021-04-21 | ClinicalTrials.gov |
| NCT04350736 | First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for … | Phase1 | Acute Lung Injury (ALI) Associated With COVID-19 | Completed | 2020-04-23 | 2020-07-01 | ClinicalTrials.gov |
| NCT04200573 | Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 | Phase1 | Symptomatic Neurogenic Orthostatic Hypertension | Completed | 2020-01-13 | 2021-08-19 | ClinicalTrials.gov |
| NCT04150341 | Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response | Phase2 | Asthma | Completed | 2019-11-06 | 2020-09-03 | ClinicalTrials.gov |
| NCT04095793 | Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in S… | Phase3 | Symptomatic Neurogenic Orthostatic Hypotension | Terminated | 2019-09-19 | 2021-11-12 | ClinicalTrials.gov |
| NCT04044339 | Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects | Phase1 | Healthy | Completed | 2019-08-08 | 2019-11-27 | ClinicalTrials.gov |
| NCT03758443 | Efficacy & Safety of TD-1473 in Ulcerative Colitis | Phase2 | Ulcerative Colitis (UC) | Terminated | 2019-03-11 | 2021-10-20 | ClinicalTrials.gov |
| NCT03829657 | Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in S… | Phase3 | Symptomatic Neurogenic Orthostatic Hypotension | Terminated | 2019-02-22 | 2021-11-10 | ClinicalTrials.gov |
| NCT03750552 | Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subj… | Phase3 | Symptomatic Neurogenic Orthostatic Hypotension | Completed | 2019-01-24 | 2021-07-21 | ClinicalTrials.gov |
| NCT03750565 | Multiple Dose Ethnobridging PK Study in Healthy Subjects | Phase1 | Inflammatory Bowel Diseases | Completed | 2018-11-27 | 2019-02-13 | ClinicalTrials.gov |
| NCT03635112 | Efficacy and Safety of TD-1473 in Crohn's Disease | Phase2 | Crohn's Disease | Terminated | 2018-11-19 | 2021-12-30 | ClinicalTrials.gov |
| NCT03652038 | Single and Multiple Ascending Dose Study of TD-8236 by Inhalation | Phase1 | Asthma | Completed | 2018-11-07 | 2020-07-13 | ClinicalTrials.gov |
| NCT03555617 | Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study | Phase1 | Inflammatory Bowel Disease | Completed | 2018-06-13 | 2018-07-15 | ClinicalTrials.gov |
| NCT03573817 | A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administere… | Phase3 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2018-05-31 | 2018-09-25 | ClinicalTrials.gov |
| NCT03432793 | Drug-Drug Interaction (DDI) Study for TD-9855 | Phase1 | Drug Drug Interaction (DDI) | Completed | 2018-02-28 | 2018-04-21 | ClinicalTrials.gov |
| NCT03408470 | TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Heal… | Phase1 | Intestinal Disorders | Completed | 2018-01-31 | 2018-02-21 | ClinicalTrials.gov |
| NCT02705755 | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | Phase2 | Neurogenic Orthostatic Hypotension | Completed | 2017-09-09 | 2018-11-28 | ClinicalTrials.gov |
| NCT03103412 | TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) | Phase1 | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | Completed | 2017-05-04 | 2017-11-08 | ClinicalTrials.gov |
| NCT03095456 | Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD | Phase3 | Chronic Obstructive Pulmonary Disease, COPD | Completed | 2017-03-27 | 2017-11-25 | ClinicalTrials.gov |
| NCT02954263 | Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects | Phase1 | Healthy Adults, Elderly Subjects | Completed | 2016-11-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02818686 | TD-1473 for Active Ulcerative Colitis (UC) | Phase1 | Ulcerative Colitis, Active Moderate | Completed | 2016-10-03 | 2018-03-29 | ClinicalTrials.gov |
| NCT02903095 | Single Ascending Dose Study of TD-1439 in Healthy Subjects | Phase1 | Healthy Subjects | Completed | 2016-09-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02820311 | Thorough QT (TQT) Study of TD-4208 in Healthy Subjects | Phase1 | Cardiac Repolarization in Healthy Subjects | Completed | 2016-05-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02753855 | Pharmacokinetics of Telavancin in Normal and Obese Subjects | Phase1 | Healthy | Completed | 2016-04-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02709928 | Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects | Phase1 | Healthy Adults, Elderly Subjects | Completed | 2016-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02663089 | A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metaboli… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-02-08 | 2016-03-17 | ClinicalTrials.gov |
| NCT02657122 | SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) o… | Phase1 | Healthy | Completed | 2015-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02578082 | Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment | Phase1 | Renal Impairment | Completed | 2015-12-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02639078 | Single Ascending Dose Study of TD-0714 in Healthy Subjects | Phase1 | Healthy | Completed | 2015-11-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02581592 | Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2015-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02512510 | Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (… | Phase3 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02459080 | Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (… | Phase3 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02518139 | A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmona… | Phase3 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2015-09-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02392208 | Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chron… | Phase4 | End-Stage Renal Disease | Completed | 2015-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02772159 | TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Heal… | Phase1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2015-06-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02267525 | The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (D… | Phase2 | Gastroparesis | Completed | 2014-12-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02116543 | TD-6450 MAD Study in HCV Infected Subjects | Phase1 | Hepatitis C | Completed | 2014-05-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02040792 | A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disea… | Phase2 | COPD | Completed | 2014-05-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02109172 | A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Ch… | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2014-04-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02022306 | TD-6450 SAD and MAD in Healthy Subjects | Phase1 | Hepatitis C | Completed | 2014-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01953081 | A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Phar… | Phase1 | Enteral Feeding Intolerance | Completed | 2014-01-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01924143 | TD-9855 Mass Balance Study | Phase1 | ADHD | Completed | 2013-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01949103 | TD-1607 MAD Study in Healthy Subjects | Phase1 | Infections | Completed | 2013-10-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01791049 | TD-1607 SAD Study in Healthy Subjects | Phase1 | Serious Infections Due to Known or Suspected Gram-positive Pathogens | Completed | 2013-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01704404 | 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease | Phase2 | COPD | Completed | 2012-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01718938 | Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis | Phase2 | Gastroparesis | Completed | 2012-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01693692 | Phase 2 Study of TD-9855 to Treat Fibromyalgia | Phase2 | Fibromyalgia | Completed | 2012-11-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01644240 | A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and… | Phase1 | Gastrointestinal Motility Disorder | Terminated | 2012-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01458340 | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADH… | Phase2 | Attention-Deficit/Hyperactivity Disorder | Completed | 2011-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01467726 | Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly … | Phase1 | Alzheimer's Disease | Completed | 2011-11-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT03064113 | Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disea… | Phase2 | Chronic Obstructive Pulmonary Disease, COPD | Completed | 2011-05-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01321879 | Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gra… | Phase2 | Infection | Completed | 2011-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00674817 | An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And … | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-04-01 | 2008-10-19 | ClinicalTrials.gov |
| NCT00687700 | A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volu… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-03-10 | 2008-05-27 | ClinicalTrials.gov |
| NCT00550225 | Succinate Salt Version of GSK961081 for Healthy Volunteers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-11-29 | 2008-01-08 | ClinicalTrials.gov |
| NCT00442832 | TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection | Phase2 | Staphylococcal Skin Infection | Completed | 2006-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00391820 | Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (AC… | Phase2 | Chronic Constipation | Completed | 2006-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00887406 | Study of GSK961081 in Healthy Volunteer Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-11-07 | 2006-10-04 | ClinicalTrials.gov |
Total clinical trials: 67
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo DPI | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Placebo ( Revefenacin and Formoterol ) | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Revefenacin 175 µg, Formoterol 20 µg | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| umeclidinium 62.5 µg and vilanterol 25 µg | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Placebo | Other | Phase PHASE2 | Opioid-induced Constipation (OIC) | COMPLETED | NCT01333540 |
| TD-1211 | Other | Phase PHASE2 | Opioid-induced Constipation (OIC) | COMPLETED | NCT01333540 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02267525 |
| Velusetrag | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02267525 |
| Placebo | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02116543 |
| TD-6450 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02116543 |
| Placebo | Other | Phase PHASE1 | Infections | COMPLETED | NCT01949103 |
| TD-1607 | Other | Phase PHASE1 | Infections | COMPLETED | NCT01949103 |
| Placebo | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02512510 |
| TD-4208 | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02512510 |
| Placebo | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02459080 |
| TD-4208 | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02459080 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02109172 |
| TD-4208 | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02109172 |
| Placebo | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01458340 |
| TD-9855 | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01458340 |
| TD-1473 Dose C | Other | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03920254 |
| TD-1473 Dose B | Other | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03920254 |
| TD-1473 Dose A | Other | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03920254 |
| Telavancin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02753855 |
| Pharmacokinetic Blood Sampling | Other | Phase PHASE4 | End-Stage Renal Disease | COMPLETED | NCT02392208 |
| Telavancin | Other | Phase PHASE4 | End-Stage Renal Disease | COMPLETED | NCT02392208 |
| Placebo - saline | Other | Phase PHASE1 | Gastrointestinal Motility Disorder | TERMINATED | NCT01644240 |
| TD-8954 | Other | Phase PHASE1 | Gastrointestinal Motility Disorder | TERMINATED | NCT01644240 |
| placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| velusetrag dose 3 | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| velusetrag dose 2 | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| velusetrag dose 1 | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| Telavancin | Other | Phase PHASE2 | Infection | COMPLETED | NCT01321879 |
| Metoclopramide | Other | Phase PHASE1 | Enteral Feeding Intolerance | COMPLETED | NCT01953081 |
| TD-8954 | Other | Phase PHASE1 | Enteral Feeding Intolerance | COMPLETED | NCT01953081 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04044339 |
| TD-5202 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04044339 |
| Placebo | Other | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT03750565 |
| TD-1473 - Dose C | Other | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT03750565 |
| TD-1473 - Dose B | Other | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT03750565 |
| TD-1473 - Dose A | Other | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT03750565 |
| Itraconazole | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT03555617 |
| TD-1473 | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT03555617 |
| Caffeine | Other | Phase PHASE1 | Drug Drug Interaction (DDI) | COMPLETED | NCT03432793 |
| Itraconazole | Other | Phase PHASE1 | Drug Drug Interaction (DDI) | COMPLETED | NCT03432793 |
| Fluvoxamine | Other | Phase PHASE1 | Drug Drug Interaction (DDI) | COMPLETED | NCT03432793 |
| TD-9855 | Other | Phase PHASE1 | Drug Drug Interaction (DDI) | COMPLETED | NCT03432793 |
| [14C]-TD-1473 Oral Capsule | Other | Phase PHASE1 | Intestinal Disorders | COMPLETED | NCT03408470 |
| [14C]-TD-1473 IV bolus | Other | Phase PHASE1 | Intestinal Disorders | COMPLETED | NCT03408470 |
| TD-1473 oral capsule | Other | Phase PHASE1 | Intestinal Disorders | COMPLETED | NCT03408470 |
| Placebo | Other | Phase PHASE1 | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | COMPLETED | NCT03103412 |
| 15N2-tofacitinib | Other | Phase PHASE1 | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | COMPLETED | NCT03103412 |
| TD-3504 | Other | Phase PHASE1 | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | COMPLETED | NCT03103412 |
| Placebo | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02022306 |
| TD-6450 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02022306 |
| TD-1211 Dose 2 | Other | Phase PHASE1 | Constipation | COMPLETED | NCT01655771 |
| TD-1211 Dose 1 | Other | Phase PHASE1 | Constipation | COMPLETED | NCT01655771 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02903095 |
| TD-1439 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02903095 |
| Placebo | Other | Phase PHASE1 | Healthy Adults, Elderly Subjects | COMPLETED | NCT02709928 |
| TD-0714 | Other | Phase PHASE1 | Healthy Adults, Elderly Subjects | COMPLETED | NCT02709928 |
| Placebo for MAD | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| TD-1473 for MAD | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| Placebo for SAD | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| TD-1473 for SAD | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| TD-9855 | Other | Phase PHASE1 | ADHD | COMPLETED | NCT01924143 |
| Placebo | Other | Phase PHASE1 | Serious Infections Due to Known or Suspected Gram-positive Pathogens | COMPLETED | NCT01791049 |
| TD-1607 | Other | Phase PHASE1 | Serious Infections Due to Known or Suspected Gram-positive Pathogens | COMPLETED | NCT01791049 |
| Placebo | Other | Phase PHASE1 | Healthy Adults, Elderly Subjects | COMPLETED | NCT02954263 |
| TD-1439 | Other | Phase PHASE1 | Healthy Adults, Elderly Subjects | COMPLETED | NCT02954263 |
| TD-1211 PO [C14] | Other | Phase PHASE1 | OIC | COMPLETED | NCT01702194 |
| TD-1211 IV [C14] | Other | Phase PHASE1 | OIC | COMPLETED | NCT01702194 |
| TD-1211+ itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01568411 |
| TD-1211 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01568411 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01040637 |
| TD-1211 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01040637 |
| Placebo | Other | Phase PHASE2 | Opioid Induced Constipation | COMPLETED | NCT01459926 |
| TD-1211 | Other | Phase PHASE2 | Opioid Induced Constipation | COMPLETED | NCT01459926 |
| TD-1473 [Tablet B] | Other | Phase PHASE1 | Intestinal Disorder | COMPLETED | NCT04587713 |
| TD-1473 [Tablet A] | Other | Phase PHASE1 | Intestinal Disorder | COMPLETED | NCT04587713 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Moxifloxacin | Other | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Ampreloxetine Placebo | Other | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Ampreloxetine <Dose B> | Other | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Ampreloxetine <Dose A> | Other | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Placebo | Other | Phase PHASE2 | Opioid Induced Constipation | COMPLETED | NCT01401985 |
| TD-1211 | Other | Phase PHASE2 | Opioid Induced Constipation | COMPLETED | NCT01401985 |
| Placebo | Other | Phase PHASE1 | Acute Lung Injury (ALI) Associated With COVID-19 | COMPLETED | NCT04350736 |
| TD-0903 | Other | Phase PHASE1 | Acute Lung Injury (ALI) Associated With COVID-19 | COMPLETED | NCT04350736 |
| Ampreloxetine | Other | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04200573 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03652038 |
| TD-8236 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03652038 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis, Active Moderate | COMPLETED | NCT02818686 |
| TD-1473 | Other | Phase PHASE1 | Ulcerative Colitis, Active Moderate | COMPLETED | NCT02818686 |
| GSK961081 dry powder for inhalation | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02663089 |
| [14C]-GSK961081 oral solution | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02663089 |
| [14C]-GSK961081 solution for IV infusion | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02663089 |
| Placebo Comparator | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02639078 |
| TD-0714 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02639078 |
| Nezulcitinib (TD-0903) Dose B | Other | Phase PHASE1 | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | COMPLETED | NCT05091723 |
| Nezulcitinib (TD-0903) Dose A | Other | Phase PHASE1 | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | COMPLETED | NCT05091723 |
| albuterol sulfate (nebulizer) | Other | Preclinical | COVID-19 | COMPLETED | NCT04681079 |
| albuterol sulfate (MDI) | Other | Preclinical | COVID-19 | COMPLETED | NCT04681079 |
| Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis (IPF) | TERMINATED | NCT04589260 |
| TD-1058 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis (IPF) | TERMINATED | NCT04589260 |
| Formoterol | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03573817 |
| Placebo | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03573817 |
| Revefenacin | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03573817 |
| Placebo for Spiriva Handihaler® | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03095456 |
| Placebo for Revefenacin | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03095456 |
| Spiriva Handihaler® | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03095456 |
| Revefenacin | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03095456 |
| Ipratropium 500 μg | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03064113 |
| TD-4208 350 μg | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03064113 |
| TD-4208 700 μg | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03064113 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03064113 |
| Moxifloxacin 400 mg | Other | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| Placebo for TD-4208 | Other | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| TD-4208 700 mcg | Other | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| TD-4208 175 mcg | Other | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| TD-4208 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02772159 |
| TD-4208 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT02581592 |
| TD-4208 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT02578082 |
| Tiotropium | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02518139 |
| TD-4208 | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02518139 |
| Placebo | Other | Phase PHASE2 | COPD | COMPLETED | NCT02040792 |
| TD-4208 | Other | Phase PHASE2 | COPD | COMPLETED | NCT02040792 |
| Placebo | Other | Phase PHASE2 | COPD | COMPLETED | NCT01704404 |
| TD-4208 | Other | Phase PHASE2 | COPD | COMPLETED | NCT01704404 |
| Placebo | Other | Phase PHASE2 | Fibromyalgia | COMPLETED | NCT01693692 |
| TD-9855 Group 2 | Other | Phase PHASE2 | Fibromyalgia | COMPLETED | NCT01693692 |
| TD-9855 Group 1 | Other | Phase PHASE2 | Fibromyalgia | COMPLETED | NCT01693692 |
| Placebo | Other | Phase PHASE2 | Acute Lung Injury (ALI) Associated With COVID-19 | COMPLETED | NCT04402866 |
| TD-0903 | Other | Phase PHASE2 | Acute Lung Injury (ALI) Associated With COVID-19 | COMPLETED | NCT04402866 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT04150341 |
| TD-8236 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT04150341 |
| Placebo | Other | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | COMPLETED | NCT03750552 |
| ampreloxetine | Other | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | COMPLETED | NCT03750552 |
| Placebo | Other | Phase PHASE2 | Neurogenic Orthostatic Hypotension | COMPLETED | NCT02705755 |
| TD-9855 | Other | Phase PHASE2 | Neurogenic Orthostatic Hypotension | COMPLETED | NCT02705755 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03758443 |
| TD-1473 Dose C | Other | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03758443 |
| TD-1473 Dose B | Other | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03758443 |
| TD-1473 Dose A | Other | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03758443 |
| ampreloxetine | Other | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | TERMINATED | NCT04095793 |
| Placebo | Other | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | TERMINATED | NCT03829657 |
| ampreloxetine | Other | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | TERMINATED | NCT03829657 |
| TD-1473 | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT03635112 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT03635112 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01467726 |
| Velusetrag | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01467726 |
| Ipratropium Bromide | Other | Phase PHASE2 | COPD | COMPLETED | NCT04315558 |
| Revefenacin Inhalation Solution [Yupelri] | Other | Phase PHASE2 | COPD | COMPLETED | NCT04315558 |
| Placebo DPI | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Placebo ( Revefenacin and Formoterol ) | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Revefenacin 175 µg, Formoterol 20 µg | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| umeclidinium 62.5 µg and vilanterol 25 µg | Other | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Placebo | Other | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | ACTIVE_NOT_RECRUITING | NCT05696717 |
| Ampreloxetine | Other | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | ACTIVE_NOT_RECRUITING | NCT05696717 |
| Placebo DPI | DRUG | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Placebo ( Revefenacin and Formoterol ) | DRUG | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Revefenacin 175 µg, Formoterol 20 µg | DRUG | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| umeclidinium 62.5 µg and vilanterol 25 µg | DRUG | Phase PHASE4 | COPD (Chronic Obstructive Pulmonary Disease) | RECRUITING | NCT07133880 |
| Nezulcitinib (TD-0903) Dose B | DRUG | Phase PHASE1 | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | COMPLETED | NCT05091723 |
| Nezulcitinib (TD-0903) Dose A | DRUG | Phase PHASE1 | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | COMPLETED | NCT05091723 |
| Moxifloxacin Placebo | DRUG | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Moxifloxacin | DRUG | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Ampreloxetine Placebo | DRUG | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Ampreloxetine <Dose B> | DRUG | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| Ampreloxetine <Dose A> | DRUG | Phase PHASE1 | Symptomatic Neurogenic Orthostatic Hypertension | COMPLETED | NCT04688632 |
| albuterol sulfate (nebulizer) | DRUG | Preclinical | COVID-19 | COMPLETED | NCT04681079 |
| albuterol sulfate (MDI) | DRUG | Preclinical | COVID-19 | COMPLETED | NCT04681079 |
| TD-1058 | DRUG | Phase PHASE1 | Idiopathic Pulmonary Fibrosis (IPF) | TERMINATED | NCT04589260 |
| TD-1473 [Tablet B] | DRUG | Phase PHASE1 | Intestinal Disorder | COMPLETED | NCT04587713 |
| TD-1473 [Tablet A] | DRUG | Phase PHASE1 | Intestinal Disorder | COMPLETED | NCT04587713 |
| TD-0903 | DRUG | Phase PHASE2 | Acute Lung Injury (ALI) Associated With COVID-19 | COMPLETED | NCT04402866 |
| Ampreloxetine | DRUG | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | ACTIVE_NOT_RECRUITING | NCT05696717 |
| TD-5202 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04044339 |
| TD-1473 Dose C | DRUG | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03920254 |
| TD-1473 Dose B | DRUG | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03920254 |
| TD-1473 Dose A | DRUG | Phase PHASE2 | Ulcerative Colitis (UC) | TERMINATED | NCT03920254 |
| TD-1473 - Dose C | DRUG | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT03750565 |
| TD-1473 - Dose B | DRUG | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT03750565 |
| TD-1473 - Dose A | DRUG | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT03750565 |
| ampreloxetine | DRUG | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | TERMINATED | NCT04095793 |
| TD-8236 | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT04150341 |
| Formoterol | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03573817 |
| Caffeine | DRUG | Phase PHASE1 | Drug Drug Interaction (DDI) | COMPLETED | NCT03432793 |
| Itraconazole | DRUG | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT03555617 |
| Fluvoxamine | DRUG | Phase PHASE1 | Drug Drug Interaction (DDI) | COMPLETED | NCT03432793 |
| [14C]-TD-1473 Oral Capsule | DRUG | Phase PHASE1 | Intestinal Disorders | COMPLETED | NCT03408470 |
| [14C]-TD-1473 IV bolus | DRUG | Phase PHASE1 | Intestinal Disorders | COMPLETED | NCT03408470 |
| TD-1473 oral capsule | DRUG | Phase PHASE1 | Intestinal Disorders | COMPLETED | NCT03408470 |
| 15N2-tofacitinib | DRUG | Phase PHASE1 | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | COMPLETED | NCT03103412 |
| TD-3504 | DRUG | Phase PHASE1 | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | COMPLETED | NCT03103412 |
| Placebo for Spiriva Handihaler® | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03095456 |
| Placebo for Revefenacin | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03095456 |
| Revefenacin | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03573817 |
| Ipratropium 500 μg | DRUG | Phase PHASE2 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03064113 |
| TD-4208 350 μg | DRUG | Phase PHASE2 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03064113 |
| TD-4208 700 μg | DRUG | Phase PHASE2 | Chronic Obstructive Pulmonary Disease, COPD | COMPLETED | NCT03064113 |
| TD-1439 | DRUG | Phase PHASE1 | Healthy Adults, Elderly Subjects | COMPLETED | NCT02954263 |
| Moxifloxacin 400 mg | DRUG | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| Placebo for TD-4208 | DRUG | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| TD-4208 700 mcg | DRUG | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| TD-4208 175 mcg | DRUG | Phase PHASE1 | Cardiac Repolarization in Healthy Subjects | COMPLETED | NCT02820311 |
| TD-1473 | DRUG | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT03635112 |
| GSK961081 dry powder for inhalation | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02663089 |
| [14C]-GSK961081 oral solution | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02663089 |
| [14C]-GSK961081 solution for IV infusion | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02663089 |
| Placebo for MAD | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| TD-1473 for MAD | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| Placebo for SAD | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| TD-1473 for SAD | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02657122 |
| Placebo Comparator | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02639078 |
| TD-0714 | DRUG | Phase PHASE1 | Healthy Adults, Elderly Subjects | COMPLETED | NCT02709928 |
| Tiotropium | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02518139 |
| Pharmacokinetic Blood Sampling | PROCEDURE | Phase PHASE4 | End-Stage Renal Disease | COMPLETED | NCT02392208 |
| TD-6450 | DRUG | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02116543 |
| Metoclopramide | DRUG | Phase PHASE1 | Enteral Feeding Intolerance | COMPLETED | NCT01953081 |
| TD-1607 | DRUG | Phase PHASE1 | Infections | COMPLETED | NCT01949103 |
| placebo | DRUG | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| velusetrag dose 3 | DRUG | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| velusetrag dose 2 | DRUG | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| velusetrag dose 1 | DRUG | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01718938 |
| TD-4208 | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02772159 |
| TD-1211 PO [C14] | DRUG | Phase PHASE1 | OIC | COMPLETED | NCT01702194 |
| TD-1211 IV [C14] | DRUG | Phase PHASE1 | OIC | COMPLETED | NCT01702194 |
| TD-9855 Group 2 | DRUG | Phase PHASE2 | Fibromyalgia | COMPLETED | NCT01693692 |
| TD-9855 Group 1 | DRUG | Phase PHASE2 | Fibromyalgia | COMPLETED | NCT01693692 |
| TD-1211 Dose 2 | DRUG | Phase PHASE1 | Constipation | COMPLETED | NCT01655771 |
| TD-1211 Dose 1 | DRUG | Phase PHASE1 | Constipation | COMPLETED | NCT01655771 |
| Placebo - saline | DRUG | Phase PHASE1 | Gastrointestinal Motility Disorder | TERMINATED | NCT01644240 |
| TD-8954 | DRUG | Phase PHASE1 | Enteral Feeding Intolerance | COMPLETED | NCT01953081 |
| TD-1211+ itraconazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01568411 |
| Velusetrag | DRUG | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02267525 |
| TD-9855 | DRUG | Phase PHASE1 | Drug Drug Interaction (DDI) | COMPLETED | NCT03432793 |
| Telavancin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02753855 |
| Placebo | DRUG | Phase PHASE3 | Symptomatic Neurogenic Orthostatic Hypotension | ACTIVE_NOT_RECRUITING | NCT05696717 |
| TD-1211 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01568411 |
| Placebo RD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 300mcg RD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 100mcg RD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 300mcg SD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 200mcg SD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 100mcg SD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| Placebo SD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 50mcg SD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 3mcg SD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| GSK961081 15mcg SD | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00887406 |
| Propranolol matching placebo | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00687700 |
| Propranolol | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00687700 |
| 1200 microgrammes GSK961081 | DRUG | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00674817 |
| 400 microgrammes GSK961081 | DRUG | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00674817 |
| GSK961081 matching placebo | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00687700 |
| GSK961081 | DRUG | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00687700 |
| Vancomycin | DRUG | Phase PHASE2 | Staphylococcal Skin Infection | COMPLETED | NCT00442832 |
| TD-1792 | DRUG | Phase PHASE2 | Staphylococcal Skin Infection | COMPLETED | NCT00442832 |
| TD-5108 | DRUG | Phase PHASE2 | Chronic Constipation | COMPLETED | NCT00391820 |
Total products: 259